Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H25N5O5.ClH |
Molecular Weight | 487.936 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4
InChI
InChIKey=AQAZIYFEPYHLHC-UHFFFAOYSA-N
InChI=1S/C23H25N5O5.ClH/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H25N5O5 |
Molecular Weight | 451.4751 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Originator
Sources: http://adisinsight.springer.com/drugs/800010345
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
9.27 null [pKi] | |||
9.09 null [pKi] | |||
9.09 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
|||
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
151.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
65.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
268 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Disc. AE: Sinus tachycardia... AEs leading to discontinuation/dose reduction: Sinus tachycardia (1 patient) Sources: |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
DLT: Postural edema... Dose limiting toxicities: Postural edema (2.7%) Sources: |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Disc. AE: Orthostatic dizziness... AEs leading to discontinuation/dose reduction: Orthostatic dizziness (1 patient) Sources: |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Disc. AE: Fatigue, Urinary incontinence... Other AEs: Rhinitis... AEs leading to discontinuation/dose reduction: Fatigue (3 patients) Other AEs:Urinary incontinence (2 patients) Rhinitis (1 patient) Sources: |
8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Other AEs: Nausea, Constipation... Other AEs: Nausea (below serious, 2 patients) Sources: Constipation (below serious, 1 patient) Allergy (below serious, 1 patient) Dizziness (below serious, 1 patient) Numbness (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinus tachycardia | 1 patient Disc. AE |
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Postural edema | 2.7% DLT |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
Orthostatic dizziness | 1 patient Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Rhinitis | 1 patient | 16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Urinary incontinence | 2 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Fatigue | 3 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Allergy | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Constipation | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Dizziness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Numbness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Nausea | below serious, 2 patients | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: Boceprevir may increase doxazosin concentrations through CYP3A inhibition |
|||
minor | ||||
minor | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. | 2001 |
|
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. | 2001 |
|
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. | 2001 |
|
Is postural hypotension a real problem with antihypertensive medication? | 2001 |
|
A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension. | 2001 |
|
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. | 2001 Aug |
|
Lessons learned from prematurely terminated clinical trials. | 2001 Aug |
|
Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1. | 2001 Aug 1 |
|
Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. | 2001 Dec |
|
5alpha-reductase inhibitors: what role should they play? | 2001 Dec |
|
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects. | 2001 Jan |
|
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is Cadura safe? | 2001 Jul |
|
Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. | 2001 Jul |
|
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. | 2001 Jul |
|
[Doxazosin and soluble guanylate cyclase in a rat model of hypertension]. | 2001 Jul |
|
Role of alpha1-blockade in congenital long QT syndrome: investigation by exercise stress test. | 2001 Jul |
|
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. | 2001 Jul 1 |
|
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy. | 2001 Jul-Aug |
|
Low-dose alpha/beta blockade in the treatment of essential hypertension. | 2001 Jun |
|
Voltammetric determination of doxazosin in tablets using rotating platinum electrode. | 2001 Jun |
|
US FDA weighs options for warning on antihypertensive drug. | 2001 Jun 2 |
|
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia. | 2001 Jun 7 |
|
[Long-term therapy of benign prostatic hyperplasia. Our experience]. | 2001 Mar |
|
Update in pharmacologic treatment of hypertension. | 2001 May |
|
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. | 2001 May |
|
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension. | 2001 May |
|
Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. | 2001 May 17 |
|
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice]. | 2001 May 31 |
|
[Doksazozin "Cardura" in acute urinary retention caused by benign prostatic hyperplasia]. | 2001 May-Jun |
|
Effects of antihypertensive agents on blood pressure during exercise. | 2001 Nov |
|
Doxazosin and congestive heart failure. | 2001 Nov 1 |
|
Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. | 2001 Oct |
|
A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. | 2001 Oct |
|
Warning for antihypertensive drug? | 2001 Oct 6 |
|
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. | 2001 Sep |
|
Heart lines. Cardura update. | 2001 Sep |
|
The choice of antihypertensive drugs in patients with erectile dysfunction. | 2002 |
|
Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. | 2002 |
|
Influence of the alpha-1-adrenergic receptor blocker doxazosin on exercise-induced hyperkalemia in hemodialysis patients. | 2002 |
|
[Doxazosin, of modified liberation, in hemodialyzed patients]. | 2002 Apr |
|
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. | 2002 Aug |
|
Medical therapy for benign prostatic hyperplasia progression. | 2002 Aug |
|
Critical evaluation of the problem of chronic urinary retention after orthotopic bladder substitution in women. | 2002 Aug |
|
Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. | 2002 Feb |
|
The use of alpha-adrenoceptor antagonists in lower urinary tract disease. | 2002 Feb |
|
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. | 2002 Feb |
|
Psychological characteristics and responses to antihypertensive drug therapy. | 2002 Jan-Feb |
|
Treatment of hypertension in the elderly. | 2002 Jan-Feb |
|
Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin. | 2002 Mar |
|
Premature termination of clinical trials--lessons learned. | 2002 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/doxazosin.html
Usual Adult Dose for Hypertension
Initial dose: 1 mg orally once a day.
Maintenance dose: 1 to 16 mg orally once a day.
Usual Adult Dose for Benign Prostatic Hyperplasia
Initial dose:
Immediate-release: 1 mg orally once a day.
Extended-release: 4 mg orally once a day with breakfast
Maintenance dose:
Immediate-release: 1 to 8 mg orally once a day.
Extended-release: 4 to 8 mg orally once a day with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg (the maximum recommended dose). The recommended titration interval is 3 to 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2977161
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 17:03:23 UTC 2023
by
admin
on
Thu Jul 06 17:03:23 UTC 2023
|
Record UNII |
Y9EDC2483R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00469077
Created by
admin on Thu Jul 06 17:03:23 UTC 2023 , Edited by admin on Thu Jul 06 17:03:23 UTC 2023
|
PRIMARY | |||
|
70918-01-3
Created by
admin on Thu Jul 06 17:03:23 UTC 2023 , Edited by admin on Thu Jul 06 17:03:23 UTC 2023
|
PRIMARY | |||
|
Y9EDC2483R
Created by
admin on Thu Jul 06 17:03:23 UTC 2023 , Edited by admin on Thu Jul 06 17:03:23 UTC 2023
|
PRIMARY | |||
|
11591230
Created by
admin on Thu Jul 06 17:03:23 UTC 2023 , Edited by admin on Thu Jul 06 17:03:23 UTC 2023
|
PRIMARY | |||
|
105314-71-4
Created by
admin on Thu Jul 06 17:03:23 UTC 2023 , Edited by admin on Thu Jul 06 17:03:23 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |